ProfileGDS5678 / 1424305_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 31% 32% 32% 33% 31% 32% 32% 32% 32% 33% 35% 33% 32% 32% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7428531
GSM967853U87-EV human glioblastoma xenograft - Control 22.7306632
GSM967854U87-EV human glioblastoma xenograft - Control 32.7344632
GSM967855U87-EV human glioblastoma xenograft - Control 42.7001133
GSM967856U87-EV human glioblastoma xenograft - Control 52.6619831
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7929432
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7877232
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7129932
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7098432
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7279133
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7907135
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7128333
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7223532
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7222432